📝 [190+ Pages Report] Global Congenital Hyperinsulinism Treatment Market size & share revenue was valued at around US$ 206.0 Million in 2022 and is estimated to grow about US$ 319.9 Million by 2030, at a CAGR of approximately 5.7% between 2022 and 2030.
Insulin is the hormone that regulates blood sugar levels, and congenital hyperinsulinism (CHI) is a disorder that results in abnormally high levels of insulin in an individual. Congenital hyperinsulinism has several subtypes, such as diffuse KATP HI, exercise-induced HI, focal KATP HI, GDH HI or HI/HA, GK HI, HNF4A/HNF1A HI, and SCHAD. Extremely uncontrolled insulin production from pancreatic beta cells may result in severe lifetime neurodegeneration and permanent brain damage. Congenital hyperinsulinism has many subtypes and classifications, such as Focal HI, Diffuse HI, K-ATP mutant HI, Transient HI, Persistent HI, etc. The initial goal of treatment is to stabilise the level of insulin using techniques like glucagon treatment and continuous glucagon infusions, among others.
Request FREE Sample Report (Including Full TOC, Table & Figures):
https://www.coherentmarketinsights.com/insight/request-sample/5329
Our Sample Report Consists of the Following:
- Introduction, Overview, and in-depth industry analysis are all included in the 2021 updated report.
- The COVID-19 Pandemic Outbreak Impact Analysis is included in the package
- About 190+ Pages Research Report (Including Recent Research)
- Provide detailed chapter-by-chapter guidance on Request
- Updated Regional Analysis with Graphical Representation of Size, Share, and Trends for the Year 2021
- Includes Tables and figures have been updated
- The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis
- Coherent Market Insights research methodology
⏩ Market Drivers:
The global market for treatments for congenital hyperinsulinism is anticipated to be driven by rising public awareness of the condition. For instance, Congenital Hyperinsulinism International, a volunteer, non-profit organisation dedicated to promoting awareness among those affected by CHI and offering support to those with CHI, such as disease diagnosis and disease management. The organisation hosted a family conference on August 16, 2022, when prominent researchers, physicists, physicians, and patients with their families were presented. The conference was conducted to discuss patient and family experiences, raise awareness of the illness, and learn about all facets of the illness and its treatments.
During the projected period, an increase in research and development activities for the creation of congenital hyperinsulinism medications is anticipated to fuel market expansion. As an illustration, in October 2021, Hanmi Pharm.Co., Ltd., a pharmaceutical company, began a Phase 2 Clinical trial for HM15136 to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136, a Glucagon analogue chemically conjugated with constant region of human immunoglobulin via non-peptidyl flexible linker, used as add-on therapy in subjects with CHI with persistent hypoglycemia.
⏩Impact – COVID-19:
Three key ways that COVID-19 can effect the economy are directly impacting medication demand and production, disrupting the flow of goods through distribution networks, and having an economic impact on businesses and financial markets. Many nations, including China, India, Saudi Arabia, the United Arab Emirates, Egypt, and others, are having difficulty moving pharmaceuticals from one location to another as a result of nationwide lockdowns.
Additionally, COVID-19 is negatively impacted by clinical trials for endocrinal disease medications and treatments. A Nepal Journal of Epidemiology report, for instance, stated that the COVID-19 pandemic had a negative impact on the clinical trial activities of endocrine illnesses including congenital hyperinsulinism in September 2020. The number of new patients and subjects enrolled in clinical trials decreased as a result of mitigation measures including self-isolation and the difficulty of accessing medical facilities during a pandemic. Clinical trial enrollment of new subjects was seen to decline by 64% between March 2019 and March 2020, 91% between April 2019 and April 2020, and 89% between May 2019 and May 2020.
Directly Purchase a copy of Business Report:
https://www.coherentmarketinsights.com/insight/buy-now/5329
⏩ Key Developments:
One of the main treatments for congenital hyperinsulinism, glucagon, has shown encouraging success in treating the condition. For instance, on March 16, 2022, the biopharmaceutical business Xeris Pharmaceuticals, Inc. will release the GVOKE kit (Glucagon Injection), a treatment for congenital hyperinsulinism that contains liquid stable glucagon. In a clinical trial where GVOKE was tested on 31 children with type 1 diabetes, 100% (30/30) of the children saw an increase in blood glucose levels to acceptable ranges.
This kit is recommended for the treatment of severe hypoglycemia in diabetic children and adults 2 years of age and older.
⏩ Market Restraint:
The high cost of first-line therapy’s total annual treatment is one of the main reasons impeding the growth of congenital hyperinsulinism treatments market. For instance, the cost of illness for CHI patients was US$ 13,144,870 annually, with an average cost per patient of US$ 2,083.19. This is based on data from the BioMedCentral Journal, an Orphanet Journal of Rare Diseases, published in July 2018 that shows the total annual cost of first line therapy is significantly high for congenital hyperinsulinism due to lack of response. The cost distribution for CHI patients was skewed, with 5.9% of patients (95 individuals in their first year of life) accounting for 61.8% (U.S. $2105491) of the overall expenses, which is significant when compared to first-line treatments.
⏩ Key Players:
Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, USV Private Limited, Xeris Pharmaceuticals, Inc., Amphaster Pharmaceuticals, Inc., Rezolute, Inc., Novo Nordisk A/S, Hanmi Pharm.Co., Ltd., e5 Pharma,LLC, Fresenius Kabi AG, Jolly Healthcare, Eiger BioPharmaceuticals, AmideBio,LLC, and Crinetics Pharmaceuticals, Inc., are significant market participants.
Download PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/5329
Key Offerings:
- Market Size & Forecast by Revenue | 2022−2030
- Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities
- Market Segmentation – A detailed analysis By business function, By component, By deployment type, By organization size, By industry vertical, and By Region
- Competitive Landscape – Top Key Vendors and Other Prominent Vendors
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Disease Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
- Market Dynamics
- Global Congenital Hyperinsulinism Treatment Market, By Disease Type, 2017-2030,(US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- KATP-HI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- GDH-HI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- GK-HI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Other (SCHAD HI, HNF4A/HNF1A HI, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- Global Congenital Hyperinsulinism Treatment Market, By Drug Type, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Diazoxide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Octreotide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Glucagon
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Nifedipine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Other (Sirolimus, Chlorothiazide, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- Global Congenital Hyperinsulinism Treatment Market, By Route of Administration, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- Global Congenital Hyperinsulinism Treatment Market, By Distribution Channel, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- Global Congenital Hyperinsulinism Treatment Market, By Region, 2017 – 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Zealand Pharma A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Xeris Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Rezolute, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Hanmi Pharm.Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Fresenius Kabi AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eiger BioPharmaceuticals.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Crinetics Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AmideBio,LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Jolly Healthcare
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- e5 Pharma, LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amphastar Pharmaceuticals.Inc,
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- USV Private Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Zealand Pharma A/S
- Section
- Research Methodology
- About Us
Directly Purchase a copy of Business Report:
https://www.coherentmarketinsights.com/insight/buy-now/5329
About us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact us:
Mr. Shah
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com